1. Home
  2. NKX vs ALT Comparison

NKX vs ALT Comparison

Compare NKX & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$11.70

Market Cap

640.3M

Sector

Finance

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$3.30

Market Cap

573.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKX
ALT
Founded
2002
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
573.8M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
NKX
ALT
Price
$11.70
$3.30
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.67
AVG Volume (30 Days)
146.4K
4.0M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
4.37%
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
105.00
52 Week Low
$11.68
$2.56
52 Week High
$13.20
$6.44

Technical Indicators

Market Signals
Indicator
NKX
ALT
Relative Strength Index (RSI) 25.22 57.93
Support Level N/A $3.18
Resistance Level $12.49 $3.32
Average True Range (ATR) 0.09 0.15
MACD -0.04 0.02
Stochastic Oscillator 12.28 56.68

Price Performance

Historical Comparison
NKX
ALT

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: